X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers. Under the terms of the agreement, Sterling will produce clinical material in its cGMP facility in Germantown, Wisconsin.
Lead Product(s): Oxaliplatin,Texaphryn
Therapeutic Area: Oncology Product Name: OxaliTEX
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: OncoTEX
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2021
Details:
The NCCN Guidelines now include ZYNLONTA as a category 2A designation as a treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Lead Product(s): Loncastuximab tesirine-lpyl
Therapeutic Area: Oncology Product Name: Zynlonta
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: ADC Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
Moleculin Biotech has signed an agreement with Sterling Pharma for US production of WP1122 to support its expanded development efforts in preparation for submitting a request to the US FDA for Investigational New Drug status for WP1122 for the potential treatment of COVID-19.
Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases Product Name: WP1122
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Moleculin Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
